| 1Rituximab |
|---|
Analyte not found
Applications
Rituximab on bioZen 1.8 um SEC-3
25045
Separation Mode: Gel Filtration Chromatography (GFC)
Gel Filtration Chromatography (GFC)
SEC-3
HPLC
Pharmaceutical/Biopharmaceutical
Therapeutic / Clinical
Therapeutic / Clinical
Therapeutic / Clinical
Analytes
Details
LC Conditions (App ID: 25045)
Column: | ||||||
Brand Name: | ||||||
Part No: | ||||||
Phase Name: SEC-3 | ||||||
Elution Type: Isocratic | ||||||
Mobile Phase: A: 50 mM KH2PO4 250 mM KCl, pH 6.8 | ||||||
Gradient Profile:
| ||||||
Flow Rate: 0.35 mL/min | ||||||
Temperature: 30°C | ||||||
System: Agilent Technologies Agilent Technologies | ||||||
Detection: LC/UV (DAD, PDA) @ 280.0000000000 nm (nanometers) |
Order Items Used in This Application
00H-4772-E0
bioZen 1.8 µm SEC-3, LC Column 300 x 4.6 mm, Ea
Qty:
Similar Applications
search
Rituximab
bioZen 1.8 µm SEC-3, LC Column 300 x 4.6 mm, Ea
Gel Filtration Chromatography (GFC)
bioZen 1.6 µm Peptide PS-C18, LC Column 150 x 2.1 mm, Ea
Reversed Phase
bioZen 2.6 µm Peptide XB-C18, LC Column 150 x 2.1 mm, Ea
Reversed Phase
bioZen 1.8 µm SEC-3, LC Column 300 x 4.6 mm, Ea
Gel Filtration Chromatography (GFC)
bioZen 1.6 µm Peptide PS-C18, LC Column 150 x 2.1 mm, Ea
Reversed Phase
bioZen 2.6 µm Peptide XB-C18, LC Column 150 x 2.1 mm, Ea
Reversed Phase
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide.
CONNECT WITH US
